San Franciscan oncology specialist Nektar Therapeutics (Nasdaq: NKTR) has entered into a collaboration with Pfizer (NYSE: PFE) to evaluate several combination regimens in multiple cancer settings.
The firms will trial Nektar’s lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with the checkpoint inhibitor avelumab, the PARP inhibitor talazoparib and the androgen receptor inhibitor enzalutamide.
Nektar, Pfizer and their respective partners will each maintain global commercial rights to their respective medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze